Orlistat
- TRADE NAMES: Alli (GSK); Xenical (Roche)
- INDICATIONS: Obesity, weight reduction
- CLASS: Lipase inhibitor
- HALF-LIFE: 1–2 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acarbose, Amiodarone, Antiepileptics, Coumarins, Cyclosporine, Ergocalciferol, Ethosuximide, Lacosamide, Levothyroxine, Oxcarbazepine, Paricalcitol, Phytonadione, Tiagabine, Vigabatrin, Vitamin A, Vitamin E, Warfarin
PREGNANCY CATEGORY: B
Contra-indicated in organ transplant recipients. Orlistat interferes with the medicines used to prevent transplant rejection.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OTIC.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of orlistat in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 06/25/2020
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
